Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 06, 2024 09:34 ET | Intrommune Therapeutics
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
The asthma & allergy friendly® Certification Program Showcases Its Certified Products and Services to Thousands of Allergist, Immunologists, and Healthcare Professionals from Around the World
March 02, 2018 08:00 ET | asthma & allergy friendly Certification Program
WASHINGTON, DC., March 02, 2018 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announced today that the asthma & allergy friendly®...